

Controlled Phase II and Phase III SLE Studies that include CLASI as an efficacy endpoint

Company	Phase	Indication	
Amgen	Phase 2	DLE	Anti-IFN-gamma
Astra-Zeneca	Phase 2	SLE	Sifalimumab
Astra-Zeneca	Phase 3	SLE	Anifrolumab
Sanofi	Phase 3	SLE and CLE	Hydroxychloroquine
Celgene	Phase 2	SLE	CC-220
Biogen	Phase 2	CLE and SLE/CLE	Anti-BDCA2
Gilead	Phase 2	CLE	JAK inhibitor and filgotinib
Lilly	Phase 2	SLE	Baracitinib
Janssen	Phase 2	Skin in SLE	Ustekinumab
Mallinckrodt	Phase 4	SLE	Questcor

Completed trials that used CLASI

The CLASI can be used to evaluate lupus specific skin lesions in patients with cutaneous lupus erythematosus (CLE) or SLE.

*Expanded tables are located on page 12 of the CPIM briefing booklet.

Upcoming and ongoing trials using CLASI

Company	Phase	Indication	Status	Mechanism
Biogen	Phase 3	CLE and Skin in SLE	Close to phase 3	Anti-BDCA2
Celgene	Phase 2	Skin in SLE	Possible phase 3	CC-220
Viela	Phase 2	Skin in SLE	Ongoing	Anti-pDC
BMS	Phase 2	Skin in SLE	Ongoing	
Resolve	Phase 2	Skin in SLE	Ongoing	
Amgen	Phase 2	Skin in SLE	Close to phase 2	Anti-BAFF + anti-ICOSL
Janssen	Phase 3	Skin in SLE	Ongoing	Ustekinumab
Lilly	Phase 3	Skin in SLE	Ongoing	Baracitinib

GlaxoSmithKline	Phase 4	SLE	Ongoing	Belimumab
-----------------	---------	-----	---------	-----------